News | News By Subject | News by Disease News By Date | Search News

Ovarian cancer News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Heads Up Tesaro (TSRO): AstraZeneca PLC (AZN), Merck & Co. (MRK)'s Ovarian Cancer Drug Just Got Expanded Use From the FDA     8/18/2017
Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS) Ink Pact to Marry Their PD-1/PARP Drugs in Phase II and III     8/1/2017
Clovis Oncology (CLVS) Stock Soars as Ovarian Cancer Trial Dazzles     6/21/2017
Why High-Flying M&A Target Tesaro (TSRO) Recently Lost More Than a Quarter of Its Value     4/26/2017
FDA Clears Massachusetts Biotech Tesaro (TSRO)'s Ovarian Cancer PARP Inhibitor     3/29/2017
AstraZeneca PLC (AZN) Steals Tesaro (TSRO)'s PARP Thunder With Phase III Ovarian Cancer Data     3/16/2017
ImmunoGen (IMGN) CEO Sees Potential in Company‚Äôs Lead ADC Product     1/18/2017
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib     10/10/2016
Clovis Oncology (CLVS) Rockets as FDA Agrees to Priority Review of Rucaparib NDA     8/25/2016
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016     6/29/2016
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S.     4/27/2016
Array BioPharma (ARRY) to Abandon Testing of Ovarian Cancer Drug     4/1/2016
1,000+ Women are Suing Johnson & Johnson (JNJ) for Allegedly Covering Up Baby Powder Cancer Risk for Decades     4/1/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015     3/24/2016
Maharashtra FDA to Test Johnson & Johnson (JNJ) Baby Powder for Cancer-Causing Substances After $75 Million U.S Verdict     3/10/2016

News from Around the Web
New Technology Can Detect Tiny Ovarian Tumors, MIT Study Reveals     4/11/2017
Biotech's PARP Wars Cool Down     3/16/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
AstraZeneca PLC (AZN) Is Now A Competitive Threat To Tesaro (TSRO) In Ovarian Cancer Maintenance Therapy     10/26/2016
The Race For PARP, A New Class Of Ovarian Cancer Drugs, Heats Up     10/10/2016
What's Behind FDA's Warning Against Ovarian Cancer Screening Tests?     9/13/2016
Parasite Found In Cat Poop May Actually Help Treat Ovarian Cancer, Dartmouth College Study     7/28/2016
Simplifying Access To Gene Testing For Women With Ovarian Cancer Improves Treatment Choices And Could Save Lives, Institute Of Cancer Research, Study     7/13/2016
Breast, Ovarian Cancer Risk May Have Association With Sense Of Smell, Keck Medicine of USC Study Reveals     10/22/2015
Tea And Citrus Products Could Lower Ovarian Cancer Risk, New University of East Anglia Research Finds     10/29/2014
No Link Found Between Fertility Drugs And Cancers, University of Illinois Study     7/1/2014
Ovarian Cancer Treatment Discovered By St. Joseph's Hospital Researchers     6/23/2014
Irregular Periods: Risk Factor For Ovarian Cancer? Public Health Institute Study     4/10/2014
A Cautionary Perspective on Angelina Jolie's Double Mastectomy     5/15/2013
Ovarian Cancer Vaccine Made From Tumors Yields Responses, University of Pennsylvania Study     4/9/2013

Press Releases
AstraZeneca Canada (AZN) Release: First-In-Class BRCA-Positive Ovarian Cancer Medicine Lynparza (Olaparib) Receives Positive Pan-Canadian Oncology Drug Review (pCODR) Recommendation For Provincial Reimbursement     9/21/2017
DelMar Pharma Receives IND Allowance From FDA To Initiate Clinical Trials Of VAL-083 For The Treatment Of Ovarian Cancer     9/18/2017
Tesaro (TSRO) Receives Positive CHMP Opinion For ZEJULA     9/15/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Opens New Clinical Site For Novel P53 Drug Candidate In Phase II Ovarian Cancer Trial     9/14/2017
Clovis Oncology (CLVS) Presents Comprehensive Dataset From Successful Phase III ARIEL3 Maintenance Treatment Trial Of Rucaparib In Advanced Ovarian Cancer At ESMO 2017     9/8/2017
Celsion (CLSN) Announces Presentation Of OVATION Study Findings At The Upcoming AACR Special Conference     8/24/2017
Mateon Therapeutics (MATN) Announces Results From Second Interim Analysis Of CA4P Phase II/III FOCUS Study In Platinum-Resistant Ovarian Cancer     8/16/2017
TapImmune (TPIV) Amends Phase II Clinical Trial To Focus On Larger Population Of Women With Platinum-Sensitive Ovarian Cancer With Greatest Unmet Need For New Treatments     8/8/2017
Celsion (CLSN) Announces Latest Translational Data From The OVATION Study In Newly Diagnosed Advanced Ovarian Cancer Patients     8/2/2017
Aprea Announces First Patient Enrolled In Phase Ib/II Clinical Study Of APR-246 For The Treatment Of Platinum-Resistant High-Grade Serous Ovarian Cancer     8/2/2017
Mateon Therapeutics (MATN) Completes Enrollment In Phase II Portion Of FOCUS Study Of CA4P For Platinum-Resistant Ovarian Cancer     8/1/2017
First Patient Enrolled In Oncoquest's Phase I/II Study Combining Oregovomab With Hiltonol In Recurrent Ovarian Cancer     7/26/2017
Almac Discovery Is Granted Orphan Drug Designation For ALM201 Programme In Ovarian Cancer     7/6/2017
Celsion (CLSN) Announces Completion Of OVATION Study And Provides Update On Its Immunotherapy Trial In Advanced Stage III And IV Ovarian Cancer     7/5/2017
Angle Reports Successful Headline Data In U.S. And European Ovarian Cancer Studies In 400 Patients     7/5/2017